GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Total Stockholders Equity

Belite Bio (Belite Bio) Total Stockholders Equity : $96.47 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Belite Bio Total Stockholders Equity?

Belite Bio's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $96.47 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Belite Bio's Book Value per Share for the quarter that ended in Mar. 2024 was $3.24. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Belite Bio's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.

Belite Bio Total Stockholders Equity Historical Data

The historical data trend for Belite Bio's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio Total Stockholders Equity Chart

Belite Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
-7.04 -15.09 41.50 90.43

Belite Bio Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.17 55.72 52.79 90.43 96.47

Belite Bio  (NAS:BLTE) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Belite Bio's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(96.47-0)/29.7944
=3.24

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Belite Bio's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 96.47
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belite Bio Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Belite Bio's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Belite Bio (Belite Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Total Stockholders Equity
Comparable Companies
RXRX MNKD KNSA BCRX XNCR MIRM EQRX IRON VIR CLDX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
D01:Germany
Address
12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Website
https://www.belitebio.com
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.